These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21495242)

  • 1. NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.
    Griffiths C; Hay N; Sutcliffe F; Stevens A
    Lancet Oncol; 2011 Mar; 12(3):221-2. PubMed ID: 21495242
    [No Abstract]   [Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
    Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
    Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
    [No Abstract]   [Full Text] [Related]  

  • 3. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
    Becze E
    ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 9. Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.
    Kok VC; Kuo JT
    BMC Urol; 2016 Jul; 16(1):34. PubMed ID: 27377922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in personalised treatment of renal-cell carcinoma.
    Shariat SF; Xylinas E
    Lancet Oncol; 2012 Aug; 13(8):751-2. PubMed ID: 22759479
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
    Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Laguna MP
    J Urol; 2013 Dec; 190(6):2017. PubMed ID: 24209513
    [No Abstract]   [Full Text] [Related]  

  • 17. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib trial data cannot support first-line use.
    Jeldres C; Sun M; Perrotte P; Karakiewicz PI
    Nat Rev Urol; 2010 Jun; 7(6):307-8. PubMed ID: 20535144
    [No Abstract]   [Full Text] [Related]  

  • 20. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.